Savara Inc. (NASDAQ:SVRA) Receives $10.14 Consensus Price Target from Brokerages

Savara Inc. (NASDAQ:SVRA) has been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $10.1429.

SVRA has been the topic of a number of analyst reports. Oppenheimer initiated coverage on shares of Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 target price on the stock. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. William Blair set a $10.00 price target on shares of Savara in a report on Monday, March 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Savara in a report on Monday, March 16th.

Savara Stock Performance

Savara stock opened at $5.26 on Wednesday. The firm’s 50 day simple moving average is $5.29 and its 200 day simple moving average is $5.60. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.08 billion, a PE ratio of -9.39 and a beta of 0.26. Savara has a 1-year low of $1.98 and a 1-year high of $7.01.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, analysts expect that Savara will post -0.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Savara

A number of institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. increased its holdings in shares of Savara by 6.9% in the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock worth $197,000 after buying an additional 2,098 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Savara by 3.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock worth $420,000 after buying an additional 2,116 shares during the last quarter. Graham Capital Management L.P. increased its holdings in shares of Savara by 4.9% in the 4th quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock worth $338,000 after buying an additional 2,615 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Savara by 9.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock worth $200,000 after buying an additional 2,859 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after buying an additional 3,205 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.